Mr. Demuth is the founding President of Torrey Pines Investment, responsible for the company’s strategic investments.

Prior to his work at Torrey Pines, he worked as a business consultant to biotech startups, as General Manager of Integrated Genomics, and in several roles at The University of Chicago, including work as an Administrator and as a technology advisor to the Arch Venture corporation.

Demuth has 30 years of research and management experience in the international life science industry and academia.

Nikolay Savchuk Ph.D. is a serial entrepreneur and an experienced international investor in healthcare and IT industries for 30 years. Dr. Savchuk is the co-founder and Managing Member at Torrey Pines Investment LLC (San Diego, CA).

The scope of interest of Dr. Savchuk is life sciences, including rational drug design, drug discovery and digital health technologies. Dr. Savchuk has lead and continues to manage successful investments in pharmaceutical and drug development companies.

Dr. Savchuk obtained his MS degree in physics in 1994 and his Ph.D. in applied mathematics in 2000 from Moscow Institute of Physics and Technology. He is the inventor and author of over 100 patents and research publications.

Michael G. Palfreyman is a seasoned leader in the biotechnology and pharmaceutical industries with over 35 years experience. He has been an invited speaker and chairperson for a number of international and national conferences, is co-inventor on 35 issued US patents, 3 pending patents and co-author of over 150 scientific articles and book chapters. Dr. Palfreyman is currently Senior Scientific Advisor for Vitruvean, Inc.

Previously, Michael was VP, Program Management & Product Development at EnVivo Pharmaceuticals where he was responsible for the late stage discovery and preclinical development of two CNS drugs now demonstrating efficacy in clinical testing.

As a co-founder NOVACE Corporation, Michael worked closely with Investors and Biotechnology Companies to bring products from discovery through to the value point of clinical validation.

Before joining NOVACE, Michael held a number of executive positions at Psychiatric Genomics, Scriptgen (Anadys) Pharmaceuticals as well as Marion Merrell Dow Research Institute (Sanofi-Aventis). In addition to overseeing research programs in Psychiatric, Neurological, Cardiovascular, Cancer, Infectious, Metabolic and Respiratory Disorders, Dr. Palfreyman’s own research included discovery and development of a number of psychotherapeutic compounds for treatment of psychosis, depression, stroke, epilepsy, emesis, Parkinson’s, and Alzheimer’s diseases. Many of these compounds have entered clinical development and a number have reached the marketplace.

Eddie Rodriguez is a co-founder and partner at Teal Ventures, an early stage venture capital fund focused on disruptive innovation in digital/mobile health.

Eddie was a partner at several national law firms and a recognized corporate attorney in the venture capital and M&A fields. Eddie has represented countless startup and emerging growth companies throughout their life cycles and numerous private and public companies in M&A transactions, in industries including healthcare, medical devices, technology, fin-tech, e-commerce and telecommunications.

Eddie has co-founded several companies in the medical device and technology areas. He has also been an active investor in early stage companies in various industries.

Mr. Rodriguez received his JD from Stanford Law School, where he was the Editor-In-Chief of the Stanford Journal of International Law and the Articles Editor of the Stanford Law and Policy Review. He holds a B.A. from the University of California, Los Angeles.

Rouslan has over 20 years experience in key account and project management, business development and sales for sustainable technologies and life sciences international organizations.

He has consistently generated multi-million sales volume, negotiated and closed multiple complex broad alliance deals with academia, pharma, biotech and venture companies (VCs) operating at the directorship and board levels.

Rouslan is a dynamic and highly motivated professional with a successful track record of leading sales teams and increasing market penetration.

Rouslan has held executive roles in business development, marketing and has experience in relationship building and fostering, product marketing, and inter-cultural management.

Educated to MSc and MBA, Rouslan possesses extensive experience in the pharmaceutical industry, knowledge of the drug discovery process and strong track record and extensive experience in organizing effective sales, managing large geographic regions, cross-functional and -cultural coordination of effort as well as efficient use of multi-site resources to maximize results.

Simon has been involved in life sciences for over 25 years, including twenty years of experience in senior management at Executive and Board Director levels, from start-up phase through to public listing in the life sciences sector. Simon has a proven track record of success with over 80 commercial deals, as well as with building and managing key alliances and international customer relationships, & establishing global network across pharma, biotech, medtech and investor communities.

Mr. Bennett has been a registered and approved Growth Coach for GrowthAccelerator, helping ambitious businesses achieve rapid and sustainable growth by providing tailored expert advice. More recently, he has developed and has run a series of two- and three-day courses on "Biotech Start-Up" and "Entrepreneurship" in Europe, USA, and SE Asia.

Specialties: Business Development, Licensing and Market Research support, Alliance Management and Customer Relations to the Biotech, Medtech, Pharmaceutical and Life Sciences Industries, and Start-Up Coaching.

Christopher has been the Inventor & Program Lead at Ensemble Mind, an organic development from the Afraxis 2.0 Project, since July 2018.

He is also the founding principal of Infinity Web Digital Marketing, located in the Greater Boston Area.

Christopher is currently leading all scientific operations at Afraxis Inc., a San Diego-based CNS drug discovery technology company.

Afraxis’ core technology is the Enhanced Spine Analysis Platform (ESP) which rapidly measures structural features of large populations of synapses for in vivo or in vitro pre-clinical therapeutic efficacy evaluation related to psychiatric and neurological disorders.

Prior to this Christopher was the Director of Neurobiology for Afraxis Inc. from 2011-2013.

His research background focuses on mechanisms by which dendritic spine structure regulates synaptic plasticity and learning. This includes important fundamental discoveries regarding the role of actin modifying proteins (cofilin, PAK, myosin) in the early stabilization phases of long-term potentiation and memory.